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The accurate identification of peripheral artery disease (PAD) in patients with 
diabetes and foot ulceration is important, in order to inform timely management 
and to plan intervention including revascularisation.  A variety of non-invasive 
tests are available to diagnose PAD at the bedside, but there is no consensus as to 
the most useful test, or the accuracy of these bedside investigations when 
compared to reference imaging tests such as magnetic resonance angiography, 
computed tomography angiography, digital subtraction angiography or colour 
duplex ultrasound.  Members of the International Working Group of the Diabetic 
Foot updated our previous systematic review, to include all eligible studies 
published between 1980 and 2018.  Some 15,380 titles were screened, resulting 
in 15 eligible studies (comprising 1563 patients, of which >80% in each study had 
diabetes) that evaluated an index bedside test for PAD against a reference imaging 
test.  The primary endpoints were positive and negative likelihood ratios (PLR and 
NLR). We found that the most commonly evaluated test parameter was ankle 
brachial index (ABI) <0.9, which may be useful to suggest the presence of PAD 
(PLR 6.5) but an ABI value between 0.9-1.3 does not rule out PAD (NLR 0.31).  A 
toe brachial index (TBI) >0.75 makes the diagnosis of PAD less likely (NLR 0.14-
0.24), whereas pulse oximetry may be used to suggest the presence of PAD (if toe 
saturation <2% lower than finger saturation; PLR 17.23-30) or render PAD less 
likely (NLR 0.2-0.27).  We found that the presence of triphasic tibial waveforms 
has the best performance value for excluding a diagnosis of PAD (NLR 0.09-0.28), 
but was evaluated in only two studies.  In addition, we found that beside clinical 
examination (including palpation of foot pulses) cannot reliably exclude PAD (NLR 
0.75), as evaluated in one study.  Overall, the quality of data are generally poor and 
there is insufficient evidence to recommend one bedside test over another. Whilst 
there have been 6 additional publications in the last 4 years that met our inclusion 
criteria, more robust evidence is required to achieve consensus on the most useful 
non-invasive bedside test to diagnose PAD. 




The estimated pooled worldwide global prevalence of foot ulceration amongst 
people with diabetes is 3% (1), of which up to 50% may have underlying 
peripheral artery disease (PAD) (2). Diabetes is strongly associated with the 
presence of PAD; among individuals with diabetes in the US National Health and 
Nutrition Examination Survey in 2004, 9.6% had PAD as defined by ABI <0.9 in 
either leg, compared with 4% of individuals without diabetes (age and gender 
standardised) (3). In diabetic subjects older than 60 years, the prevalence of PAD 
was 25% (4). Evidence suggests that PAD is causally related to the development 
of a DFU, thereby leading to a higher prevalence of PAD in diabetic patients with 
DFU than in those without a DFU. A prospective study of 749 patients without 
diabetic foot ulcer identified a significant association between lower ABI and 
higher foot ulcer risk (5). 
 
The combination of diabetes and PAD substantially increases the risk of 
amputation or non-healing and of cardiovascular mortality (6) (7) (8). In the 
Eurodiale study, patients with a foot ulcer and PAD, when compared with ulcer 
patients without PAD, had healing rates of 69% vs. 84% and major amputation 
rates of 8% vs. 2%, respectively (2). Not only is PAD an independent risk factor for 
developing foot ulceration and limb loss, it is also associated with a higher risk of 
incident cardiovascular disease and of overall mortality, irrespective of symptoms 
or the populations studied (9). PAD is therefore clearly associated with poorer 
lower extremity and cardiovascular outcomes in patients with diabetes. It is 
important for healthcare professionals to recognize it promptly, and accurately, 
and to risk stratify patients and take steps to minimize its deleterious effects. 
However, many patients with diabetes and co-existing PAD present late with foot 
ulceration (10) and with few or no preceding symptoms of PAD, probably due to 
the masking of typical symptoms (such as claudication and ischaemic rest pain) 
by peripheral neuropathy. In addition, physical examination in these patients may 
not reliably exclude a diagnosis of PAD, or assess its severity. Bedside tests that 
are useful to diagnose PAD in a population of patients without diabetes may be 
rendered less accurate in patients with diabetes due to the distal distribution of 
the peripheral arterial disease, co-existing neuropathy, peripheral oedema and 
infection. Moreover in patients with diabetes the lower leg or pedal arteries can 
be less compressible on cuff inflation during external arterial pressure 
measurements due to medial sclerosis (medial arterial calcification) which can 
render tests, such as the ankle brachial index (ABI) or toe brachial index (TBI) less 
reliable (11). These tests can play a central role in diagnosing or excluding PAD 
(12), and their advantage over reference imaging tests (such as magnetic 
resonance angiography, computed tomography angiography, digital subtraction 
angiography and colour duplex ultrasound) is that they are quick, cheap, non-
invasive, may be performed at the bedside and can be used as initial screening 
tests in order to identify those patients who should go on to have formal vascular 
imaging tests. 
The aim of this systematic review was to evaluate the performance of index non-
invasive diagnostic tests against reference standard imaging techniques for 
the detection of PAD among patients with diabetes and is an update of our 
previous review (13). This systematic review forms the basis for developing the 
IWGDF Guideline on diagnosis, prognosis and management of peripheral artery 




Using the Preferred Reporting Items for Systematic Reviews and Meta-analysis 
(PRISMA) guidance (15), we updated our previous systematic review (13), guided 
by a recent consensus document on updating systematic reviews (16) and the 
IWGDF methodology document (17).  
As a start, the population of interest (P), interventions (I), comparators (C) and 
outcomes (O) were defined, and clinical questions (PICOs) were formulated 
accordingly. These definitions and PICOs were reviewed for their clinical 
relevance by the IWGDF Editorial Board and external experts worldwide, from 
various geographical regions (see acknowledgements). Final definitions and 
PICOs are integrated within this paper.  
 
We searched the MEDLINE and EMBASE databases for studies relating to the 
diagnosis of PAD amongst patients with diabetes, updating the previous search 
and therefore capturing any new records published between 14th June 2014 and 
14th September 2018. The search string can be found in Appendix A. Two 
reviewers independently screened the abstracts for inclusion and a third reviewer 
adjudicated any conflicts. Full-text articles of included abstracts were accessed 
and assessed for inclusion and data were then extracted and verified by members 
of the IWGDF PAD working group.  
 
Inclusion / exclusion criteria 
We sought to evaluate the performance and reliability of bedside tests for PAD in 
diabetic patients with and without a foot ulcer. We evaluated any bedside test that 
aimed to detect the presence of PAD in patients with diabetes. Diagnostic tests 
were considered as any specific evaluation that sought to identify the presence of 
PAD. To be eligible for inclusion, all studies were required to meet the following 
criteria: 1) evaluated a potential index diagnostic test for PAD against a standard 
reference test (including digital subtraction angiography (DSA), computed 
tomography angiography (CTA), magnetic resonance angiography (MRA) or 
colour duplex ultrasound (CDUS)); 2) reported separately on at least 10 patients 
with diabetes or, in mixed studies, more than 80% of the cohort were patients with 
diabetes.  We included studies that reported on patients with or without a foot 
ulcer. Studies were excluded if the comparison was between two reference tests, 
or if there was insufficient data with which to calculate the sensitivity / specificity 
values. Unlike our previous review, we did not include serum markers as an 
expression of possible PAD as it was concluded that such tests would have little 
added value in diagnosing PAD. 
 
Primary endpoints 
The positive likelihood ratio (PLR) and negative likelihood ration (NLR) were the 
primary endpoints for this systematic review. In order to assess the usefulness of 
bedside tests we have used likelihood ratios, which reflect a diagnostic test’s 
ability to rule in or rule out disease (18). Likelihood ratios were used to express a 
change in odds of reaching an outcome, in the context of a known pre-test 
probability of disease (i.e. knowledge or estimation of the prevalence of disease in 
the studied population). The PLR gives the change in odds of experiencing an 
outcome if the test is positive, whereas the NLR expresses a change in odds of 
experiencing an outcome if the test is negative. PLR is calculated as follows: PLR = 
sensitivity / (1 - specificity); NLR is calculated as follows: NLR = (1- sensitivity) / 
specificity. A PLR or NLR of 1.0 means that the test does not change the probability 
of the outcome over and above the pre-test probability and therefore is not a 
useful diagnostic test. As a general rule of thumb, a test is considered to have very 
good performance if PLR ≥10 (representing an increased probability of the 
specified outcome by around 45% in the presence of a positive test result) and 
NLR≤0.1 (representing a decrease in the probability of the specified outcome of 
around 45% in the presence of a negative test result) (19) (20) (21) . Generally, 
minimal change in disease probability can occur when a test is used with a PLR 
between 1 and 2 or a NLR between 0.5 and 1.  The PLR and NLR therefore provide 
a more meaningful assessment of diagnostic utility than sensitivity or specificity 
when used with the aim of disease-probability revision (Table 1).  
 
Data extraction and quality assessment 
Data extraction was undertaken and independently verified by two investigators. 
Methodological quality was assessed using the QUADAS tool, a consensus quality 
assessment tool designed specifically for diagnostic accuracy studies (22). There 
was a wide range of heterogeneity in the populations evaluated, outcomes 
reported and diagnostic tests used, and it was therefore not possible to conduct a 
meta-analysis. Instead, measures of test performance were presented for each 
diagnostic test used and summarised within and across studies. Where not 
explicitly reported, sensitivity / specificity, PLR and NLR were calculated from the 
available data and reported in our evidence table (Table 2).  
 
Evidence statements 
Finally, two investigators drew conclusions for each intervention based on the 
strength of the available evidence, formulated as evidence statements and 




In the search performed for our previous systematic review 6629 studies were 
screened (published between 1980-2014), which resulted in total of 10 
observational studies reporting data from 2585 patients with diabetes. Our 
updated search included papers published between June 2014 and June 2018; this 
search yielded 8751 titles, of which 6 observational studies ultimately met the 
inclusion criteria. After including 9 studies from the 2016 systematic review 
(having excluded one paper investigating a serum biomarker of PAD (24)), a total 
of 15 studies (comprising 1563 patients) were included in the qualitative data 
table for this updated systematic review (Table 2). The total numbers of identified, 
screened, eligible and finally included publications in both the original and the 
updated search are given in the PRISMA flowchart in Figure 1.  
 
Patient demographics 
The mean or median age of participants was reported as 66 years, with most study 
cohorts consisting primarily of men (range 47%-88%). The reporting of patient 
demographics was variable and surprisingly sparse, but, where reported, 
comorbidities were as expected - coronary artery disease in 22.9%, 
cerebrovascular disease in 10% and 40% of patients were current or ex-smokers 
(Table 2). Few studies reported the presence or absence of neuropathy and 
ulceration, despite the importance of both of these clinical features on subsequent 
outcome. Only 4 studies reported on the presence of neuropathy (25) (26) (27) 
(28), with a mean prevalence of 72%. The median prevalence of foot ulcers was 
7% amongst those studies reporting it (29) (30) (26) (27) (31) (32) (33) (28) – 
two of these studies included a population of patients of which all had a foot ulcer 
(29) (28). The mean duration of diabetes was 13.6 years amongst those studies in 
which it was reported. 
 
Reference tests to confirm PAD 
CDUS was used as the reference test for confirming PAD in 13 of the observational 
studies, whilst DSA was used in the other 2 studies. A variety of PAD definitions 
were used in the CDUS studies (Table 2), with some studies measuring change in 
velocity and others the degree of stenosis. The two studies with DSA as a reference 
test used a cut-off of >50% reduction in vessel diameter to diagnose PAD.   
 
Index beside tests and threshold values used to diagnose PAD 
It is important to note that recent international guidelines abandon the idea of 
fixed threshold values for PAD, particularly in patients with diabetes (34), and 
instead champion the use of classification systems to categorise patients into 
clinical stages correlating with outcomes. This is an important approach that also 
takes factors such as the severity of the perfusion deficit, wound characteristics 
and infection into account, when assessing the likely prognosis of a patient with 
DFU and PAD. This topic, in particular the WIfI system, is covered in the IWGDF 
systematic review of diabetic foot classifications, also published in this journal 
(35). However, in this present review, we focus on the use of bedside tests for the 
diagnosis of PAD in the ulcerated or intact foot and present the available literature 
to date, with a caveat that we must accept that there is no ‘one-fits-all’ threshold 
value for objective bedside testing that can be used in isolation to make the 
diagnosis of PAD.  
 
Amongst the studies identified, the most commonly evaluated bedside test was 
the ankle brachial index (ABI), which was reported in 13 of the studies. Two 
studies that did not use ABI (32) (36) were written by authors who previously 
reported on the use of ABI in a smaller cohort of patients (37) and a further study 
reported ankle pressure without correcting for brachial pressure (27). The 
threshold value for diagnosis of PAD was defined as <0.9 or ≤0.9 in most studies, 
however three studies used both a lower and upper threshold for diagnosis (<0.9 
or >1.3 (30) (28) and ≤0.9 or ≥1.4 (37). Three studies used toe brachial index (TBI) 
with a threshold for diagnosis of <0.7 (37) or ≤0.75 (26) (28). Systolic toe pressure 
was reported by 2 studies (using <97mmHg (36) or <50mmHg (28) as 
thresholds). Other tests used included TcPO2(27) (28), altered waveforms on 
colour wave Doppler (26) (37) (32) (28), audible Doppler waveforms (26), pulse 
reappearance time (31), change in pulse oximetry (33) and pole test (28). One 
study looked at a wide variety of subjective clinical examination tests (28).  
 
Data Synthesis and Analysis 
 
PICO 1: In a person with diabetes and an intact foot which symptoms and signs 
(clinical examination) should clinicians examine in order to identify or exclude 
peripheral artery disease? 
PICO 2: In a person with diabetes and a foot ulcer which symptoms and signs 
(clinical examination) should clinicians examine in order to identify or exclude 
peripheral artery disease? 
 
Summary of the literature 
We found no eligible studies reporting the symptoms and signs that may identify 
or exclude peripheral artery disease in patients with diabetes and an intact foot. 
We found only one eligible recent study investigating basic clinical examination in 
patients with diabetes with foot ulceration (28), which was a prospective 
observational case series of 60 out-patients and in-patients with diabetes and new 
onset foot ulceration at a tertiary hospital. This study evaluated a number of tests, 
including clinical signs (hair loss, muscle atrophy, dependent rubor, cool skin, 
purple/blue skin, capillary refill time, venous filling time, presence of neuropathy 
and palpation of foot pulses). Using CDU or flow velocity waveforms as the 
reference tests in order to confirm / define the presence of PAD, the study found 
that 33% of participants had PAD on diagnostic ultrasound. Palpation of foot 
pulses had a sensitivity of 55% and a specificity of 60% for diagnosing PAD, with 
a PLR of 1.38 and a NLR of 0.75, meaning that this clinical examination would not 
accurately rule in or exclude presence of PAD.   
 
Pulse palpation should therefore not be used to rule out a diagnosis of PAD. None 
of the other clinical features investigated were found to accurately exclude the 
diagnosis of PAD. 
 
Evidence statement: In patients with diabetes (with an intact or ulcerated foot), 
there are no clinical signs or symptoms that can accurately exclude peripheral 
artery disease. 
 
Quality of the evidence: Low. Based on one observational study of 60 patients  
 
PICO 3: In a person with diabetes, which ‘bedside’ diagnostic procedure, alone or 
in combination, has the best performance in ruling in or excluding peripheral 
artery disease? 
 
Summary of the literature 
Ankle brachial index or systolic ankle pressure 
Nine observational studies investigated the use of Doppler ABI (most commonly 
considered diagnostic if ABI<0.9) compared to CDUS, with a variety of definitions, 
to diagnose PAD based on CDUS. Eight of these studies used peak systolic velocity 
- maximum systolic velocity ratio >2, corresponding to ≥50% stenosis, or 
monophasic waveforms in any artery, whilst one had a less well defined 
parameter - ‘presence of atherosclerotic plaques or arterial calcification’ (38). 
These studies reported a sensitivity of the ABI between 45-100% and specificity 
between 58%-97%, with corresponding PLR of 1.69-23.8 and NLR of 0.02 to 0.59. 
One study also looked at oscillatory ABI, which had a PLR of 7.9 and a NLR of 0.5 
(25).  
Of the other observational studies reporting on ABI, two studies used either 
Doppler waveform (39) or colour spectral waveform (30) as reference tests. 
These studies reported markedly different PLR (24.8 and 4.0) and NLR (0.38 and 
0.12), whilst one study using DSA as the reference test (31) gave a PLR of 5.1 and 
NLR of 0.69. 
One small study compared the use of ABI in patients with (n=57) or without 
(n=32) neuropathy (26). The authors found that neuropathy does not seem to 
have a particularly adverse effect on PLR (11 in patients with neuropathy vs. 8 in 
patients with no neuropathy), however the NLR was significantly poorer in those 
patients with neuropathy (0.5 vs. 0.1), suggesting that it is a less useful test to 
exclude PAD in patients with neuropathy. No significant improvement in PLR or 
NLR was observed when studies used thresholds to account for the presence of 
incompressible vessels (i.e. abnormally raised ABI).  
 
When comparing the four studies comprising patients with intact feet versus the 
two studies including only those with a foot ulcer, the ABI was found to produce 
sensitivity 80.7% vs. 69.5%; specificity 91.5% vs. 74%, PLR 6.74 vs. 4.10; and NLR 
0.12 vs. 0.43 (median values of the combined studies), respectively.  
Overall, of the 12 studies that used ABI as an index test (regardless of reference 
test used), the median PLR was 6.5 and the median NLR was 0.31. ABI <0.9 can 
therefore be considered helpful to rule in the diagnosis of PAD, but less effectively 
rules out PAD if the ABI is within the normal range (0.9-1.3). Moreover, the ABI 
may be more useful to rule in the diagnosis of PAD in patients with intact feet, but 
is a less useful test to exclude PAD in patients with neuropathy or foot ulceration. 
 
Ankle pressure <70mmHg (vs. DSA(27) or CDUS (28)) did not appear to be 
accurate for the detection or exclusion of PAD (PLR 2.25, NLR 0.67). 
 
Toe brachial index or systolic toe pressure 
Of the three observational studies that evaluated toe brachial index (TBI), all used 
CDUS as the reference test, with a diagnostic threshold of either <0.7 (37)  or <0.75 
(26) (28).  Two studies presented data on groups with a high prevalence of 
neuropathy (>70%), finding that TBI >0.7 or >0.75 is useful to exclude PAD, while 
TBI <0.7 or <0.75 is less useful to diagnose PAD (PLR 1-3; NLR 0.14-0.24) (26) 
(28). The third study (37)  did not report on the prevalence of neuropathy, but 
found broadly similar outcomes (PLR 3.55; NLR 0.44) 
 
In a study of 60 patients with a foot ulcer, toe pressure <50mmHg was found to 
have a much better diagnostic performance (PLR 17.55) than TBI (PLR 1.63) (28) 
but this was at the expense of poorer NLR (0.56 vs. 0.24) and sensitivity (0.45 vs. 
0.89). However, when the diagnostic threshold for toe pressure was increased to 
<97mmHg in another study (36), the performance of the test reduced markedly 
(PLR 2.67). 
 
Transcutaneous oxygen pressure  
Two studies that reported on transcutaneous oxygen pressure (TcPO2) (27) (28) 
used different diagnostic thresholds (TcPO2 <50mmHg and <60mmHg) and 
compared this with  an ankle pressure of <70mmHg, with either DSA or CDUS as 
reference. One study provided only enough data to suggest that the sensitivity of 
TcPO2 was better than ankle pressure (82% vs. 67%) (27). However another study 
of patients with foot ulcers showed much lower sensitivities for TcPO2 and ankle 
pressure (28% vs. 47%), with overall minimal diagnostic value for TcPO2 (PLR 
0.81, NLR 1.1) (28). 
 
Pulse oximetry 
Two studies compared pulse oximetry with ABI, using Doppler waveform or CDUS 
as the reference test (39) (33). Both studies used the same definition (‘toe 
saturation <2% lower than finger saturation or increased by >2% when the leg is 
elevated to 12 inches higher than the horizontal plane”).  They found that pulse 
oximetry was a more useful diagnostic test than ABI, with PLR and NLR of pulse 
oximetry of 17.23-30 and 0.2-0.27, respectively, when compared to PLR and NLR 
of ABI of 5.49-24.8 and 0.09-0.37, respectively (39) (33). 
 
Doppler waveform analysis 
Four studies used Doppler waveform analysis, recording abnormal waveform at 
the tibial arteries or ankles as suggestive of PAD (26) (32) (37) (28). In all studies, 
waveform analysis performed very well with respect to NLR (0.09-0.28), although 
the PLR were less consistent and varied between 3 and 13. Abnormal waveform 
was variably defined. 
 
Pulse reappearance time 
One study looked at pulse reappearance time (PRT) after compression of the thigh 
for 3 minutes, and compared this with ABI at a threshold of <0.9 (31).  DSA was 
used as the reference test. PRT and ABI had identical PLR and very similar NLR 
when compared to DSA (PLR 5 vs. 5; NLR 0.6 vs. 0.7). However, PRT correlated 
with the severity of stenosis seen on DSA, whereas ABI did not, although this 




In this test the leg is elevated passively, with the patient supine, while the Doppler 
signal is continuously monitored and the height at which the Doppler signal is lost 
is determined. The pole test was used in one study of patients with ulcerated feet 
(28).  The PLR was found to be 10.29 and of potentially high diagnostic value but 
the NLR was of minimal value at 0.74. 
 
Evidence statements 
1. An ABI < 0.9 may be useful to suggest the diagnosis of PAD, but a value between 
0.9-1.3 does not rule out PAD, in particular in patients with neuropathy and/or a 
foot ulcer 
2. A TBI >0.75 makes the diagnosis of PAD less likely.  
3. Pulse oximetry (if toe saturation <2% lower than finger saturation or increased 
by >2% when the leg is elevated to 12 inches higher than the horizontal plane) 
may be useful to suggest the diagnosis of PAD and to render PAD less likely  
4. The presence of triphasic tibial waveforms demonstrated small to large value 
for ruling in or ruling out PAD depending on the study, and hence may be useful 
in diagnosis.  
 
Quality of the evidence 
1. Low. Based on 12 studies on ABI using different definitions of PAD with 
inconsistent results, with 1 study on the effect of neuropathy and 4 studies that 
included patients with a foot ulcer, with the majority having a high risk of bias  
2. Moderate. Based on 3 observational studies, 1 with low and 2 with moderate to 
high risk of bias 
3. Low. Based on 2 observational studies with limited number of patients with 
diabetes and PAD 
4. Low. Based on 4 observational studies with variable definitions of an abnormal 
waveform and 2 with low and 2 with moderate to high risk of bias 
 
Discussion 
Despite increasing knowledge and understanding of the deleterious effect of PAD 
on DFU outcomes, there were limited new data regarding diagnosis of the 
presence of PAD since our previous review (13). Previous studies have reported 
on the use of bedside tests to identify PAD in mixed cohorts of patients with and 
without diabetes, however there are few studies dedicated to the assessment of 
patients with diabetes, and even fewer examining patients with diabetes and a 
foot ulcer. However, it should be noted that in the period 1980-2014 we found 9 
eligible studies while in the last 4 years, 6 new studies were identified, indicating 
that this important topic is beginning to garner more interest, but certainly needs 
more sustained attention. 
 
In patients with diabetes and a foot ulcer and features suggestive of PAD, it is 
important for early referral to a specialist foot team, as the combination of these 
pathologies is associated with poorer outcomes than either in isolation (2). But to 
what extent can the clinician rely on clinical examination to rule out PAD in this 
context? The study of Vriens et al that was included in this review was the only 
study to evaluate the diagnostic performance of clinical examination and 
concluded that the negative and positive likelihood ratios of pedal pulse 
assessment (0.75, 1.38) and other aspects of clinical examination were poor (28), 
in line with other publications on this topic (40) (41).  Clinical examination alone 
is therefore an insufficient assessment of patients with diabetes and a foot ulcer. 
These data stress the importance of non-invasive diagnostic tests, irrespective of 
the presence of foot pulses.  In addition, we have not assessed the usefulness of 
symptoms to suggest the diagnosis of PAD.  Cohort studies suggest that patients 
with diabetes and PAD, compared to PAD patients without diabetes, are less likely 
to report classical intermittent claudication, but have more frequently atypical 
symptoms that may be related to co-morbidities such as neuropathy (42) . 
 
Given the high impact on outcome and the relatively high prevalence in many 
circumstances, the best method of assessing the utility of a diagnostic test for PAD 
in patients with a DFU is the NLR, which expresses a change in odds of 
experiencing an outcome if the test is negative (i.e. a test that is effective in ruling 
out PAD).  For a test to be considered useful, the NLR should be low and NLR≤0.1 
is considered to have very good performance (representing a decrease in the 
probability of the specified outcome of around 45% in the presence of a negative 
test result) (19) (20). If, for example, we assume that a prevalence of PAD is 50% 
in patients treated in a diabetic foot ulcer clinic, an ABI < 0.9 is measured in a 
patient and a PLR of 6.5 is assumed, the probability of PAD would be increased to 
approximately 87%. Vice versa if a normal Doppler waveform is found in this 
patient, for which an NLR of 0.2 is assumed, the probability of PAD is reduced to 
approximately 17%.  
In this context, it is less important for the initial test to reliably diagnose PAD, as 
the consequences of a false positive result would be less than the consequences of 
a false negative test result, i.e. in which the diagnosis may be missed. Those 
patients in whom a positive result is obtained should proceed for further 
investigations in order to confirm the presence of PAD. The next step is to 
establish the extent of the perfusion deficit and its likely impact on ulcer healing 
and amputation risk, as discussed in our IWGDF systematic review on prognosis 
(43). The final step is the identification of patients who may require 
revascularization to promote healing and prevent amputation. This decision is 
based not only on the severity of the perfusion deficit but also on wound and 
patient related factors. Once a revascularization procedure is considered, 
establishing the anatomical distribution of disease may be achieved using CDUS, 
CTA, MRA or DSA. 
 
The most commonly used bedside test to diagnose PAD is the ABI, which was 
assessed in the majority of studies included in this review. In this review, we found 
that the presence of a normal ABI (0.9-1.3) was too inaccurate to exclude PAD in 
patients with foot ulcers (NLR >0.3), however ABI <0.9 appeared useful to suggest 
the diagnosis of PAD (PLR >5 in most research).  Moreover, in patients with 
neuropathy, a normal ABI could not, in one study, effectively rule out PAD (NLR 
0.5) (26). As the vast majority of DFU patients have neuropathy this could 
therefore contribute to the poorer performance of the ABI in patients with a foot 
ulcer. Up to a third of DFU patients have incompressible lower leg arteries 
resulting in abnormally high ABI (2)   (11)  and an elevated ABI increased the 
probability of PAD in patients with diabetes, but we could not calculate the PLR or 
NLR (44) (45). In conclusion, a normal ABI cannot accurately rule out PAD, 
although an ABI < 0.9 or also an elevated ABI are suggestive of the diagnosis of 
PAD. We suggest that ABI should not be used in isolation to exclude PAD in 
patients with a diabetic foot ulcer. 
 
The digital arteries are relatively spared from calcification and the measurement 
of toe pressure (and TBI) may therefore be a more reliable alternative to ABI in 
the diagnosis of PAD. Unfortunately in patients with digital ulceration or a toe 
amputation it may not be possible to perform this examination. Four studies 
investigated the use of toe pressure (36) (28) or TBI (26) (37) (28), but only one 
study examined the use of these tests in a population of patients with foot ulcers. 
A negative test result seems somewhat more accurate to exclude PAD (NLR 0.14-
0.44), whereas a positive test result (TBI <0.75 or <0.7) appeared to be less 
accurate to rule in PAD (PLR 1.63 – 3.55). A toe pressure of <50mmHg appeared 
to have very good diagnostic ability in patients with foot ulcers (PLR 17.55) but a 
normal toe pressure was not considered accurate enough to exclude the diagnosis 
(NLR 0.56) (28). 
 
A number of studies investigated other index bedside tests, the most accurate was 
CWD with triphasic Doppler waveforms (NLR <0.2 in most cases). Pulse oximetry 
was tested in two studies (39) (33), with NLR of 0.2 and 0.27, although it was 
unclear if any patient had a foot ulcer, and the sensitivity estimates were only 77% 
and 74%.  
 
In one study of patients with intact feet, parallel testing using ABI and pulse 
oximetry improved the NLR from their individual values of 0.34 and 0.27 to 0.09 
when used in a parallel combination strategy (33), suggesting that a combination 
of tests is potentially most useful to exclude PAD.  This was the only study to 
present a parallel testing approach and further similar studies are warranted. 
Pulse oximetry is an attractive technique because it requires equipment that is 
relatively inexpensive and available in most healthcare environments, but further 
studies are necessary to define its role in diagnosing PAD in patients with a foot 
ulcer. In addition, in the experience of some of the authors who have used this 
technique, it can be difficult to obtain a reliable measurement due to practical 
issues. It is certainly important to consider the technical aspects and potential 
inter-observer variability when conducting any bedside test, however these 
aspects are out of the scope of our review. Ankle pressure, TcPO2, pulse 
reappearance time and pole test all had limited diagnostic utility (NLR >0.6 in 
most cases).  
 
No study included satisfied the QUADAS criteria for an overall “high quality” 
rating. The studies were generally of poor or moderate quality, with substantial 
heterogeneity of patient characteristics and outcome reporting. The presentation 
of data was frequently also poor, with a number of studies failing to report on the 
presence of important features such as ulceration and neuropathy. This precluded 
the production of a valid meta-analysis. 
 
In addition to the eligible observational studies included in our review, we came 
across an informative systematic review / meta-analysis of 31 studies that 
reported the use of clinical examination, as well as a number of bedside tests, to 
diagnose PAD in patients with diabetes (the majority of which did not have foot 
ulcers) (41).  It did not meet the inclusion criteria for our review, as some of the 
studies used ABI or ‘complete wound healing’ as reference tests, rather than the 
standard vascular imaging tests specified in our inclusion criteria.  In addition, the 
studies included were widely heterogeneous. Nonetheless, it provided some 
interesting comparisons. Barshes and colleagues found the presence of palpable 
foot pulses to have poor diagnostic reliability (PLR 3.06, NLR 0.57) (41), which 
corresponds to the findings of Vriens and colleagues included in our review (28),  
and suggested that strategies using non-invasive bedside tests to investigate only 
those patients with abnormal pulses had too low overall diagnostic sensitivity.  In 
addition, they reported on the use of ABI, TBI, TcP02 and skin perfusion pressure, 
all of which performed poorly when evaluating a patient with diabetes for the 
presence of PAD (NLR >0.2 in all cases). 
 
A limitation of this review is that the majority of studies used colour duplex 
ultrasound (CDUS) as the reference test, however this has its drawbacks.  CDUS 
may be less reliable in identifying significant arterial disease in the crural vessels, 
particularly in the presence of significant calcification and if doubt exists then an 
alternative method of imaging should be considered.  There is also a potential role 
for dynamic testing, such as pre- and post- exercise ABI or TBI, but these tests 
were not reported in the studies we included in our review.  
 
It seems remiss that there continues to be such a dearth of evidence in this area, 
but it is important to note the current trend away from simply diagnosing PAD. As 
discussed above, determining the presence of PAD is only the first step in 
evaluating the vascular assessment of a person with diabetes and a foot ulcer. Not 
only should we assess the presence and severity of ischaemia, but we must 
simultaneously assess the presence of neuropathy, wound characteristics, 
infection and other mitigating clinical characteristics, as discussed elsewhere in 
this issue (35)  (14).  
 
Conclusions 
Amongst the studies included in our review, an ABI <0.9 or >1.3 appears to be a 
useful test for the detection of PAD, although it has variable performance amongst 
the populations studied.  Although widely used to assess PAD at the bedside, 
palpation of peripheral pulses showed disappointingly poor performance in either 
ruling in or ruling out PAD.  Alternative bedside tests that appear accurate are 
CWD with absence of triphasic waveforms and perhaps pulse oximetry with toe 
saturation <2% lower than finger saturation or increased by >2% when the leg is 
elevated to 12 inches higher than the horizontal plane. Overall, there was 
insufficient evidence to recommend a single bedside test to reliably rule out PAD 
in a patient with a foot ulcer. In such a patient a normal ABI (or palpable pulses) 
cannot reliably rule out PAD. A second test should be performed such as 
assessment of Doppler waveforms, possibly in combination with toe pressure/TBI 
measurements. Pulse oximetry could become an attractive alternative if 
confirmed in future studies. There is clearly a need for improved reporting and for 
more informative studies of diagnostic tests for PAD in patients with diabetes in 
order to reach more robust conclusions in the future.  
  
Acknowledgements:  
We would like to thank the following external experts for their review of our PICOs 
for clinical relevance: Stephan Morbach (Germany), Heidi Corcoran (Hongkong), 
Vilma Urbančič (Slovenia), Rica Tanaka (Japan), Florian Dick (Switzerland), Taha 
Wassila (Egypt), Abdul Basit (Pakistan), Yamile Jubiz (Colombia), Sriram 
Narayanan (Singapore), Eduardo Alvarez (Cuba). 
We would like to thank Jaap J. Van Netten (on behalf of the IWGDF editorial board) 
and Neal Barshes (independent external expert) for their peer review of the 
manuscript.   
In addition, we would like to thank Jack Brownrigg for his input into the previous 
version of this systematic review. 
 
Conflict of interest statements 
Production of the 2019 IWGDF Guidelines was supported by unrestricted grants 
from: Molnlycke Healthcare, Acelity, ConvaTec, Urgo Medical, Edixomed, 
Klaveness, Reapplix, Podartis, Aurealis, SoftOx, Woundcare Circle, and Essity. 
These sponsors did not have any communication related to the systematic reviews 
of the literature or related to the guidelines with working group members during 
the writing of the guidelines, and have not seen any guideline or guideline-related 
document before publication. 
  
All individual conflict of interest statement of authors of this guideline can be 
found at: https://iwgdfguidelines.org/about-iwgdf-guidelines/biographies/ 
 
Author contributions: Rachael F performed the literature search, screened the 
titles, abstracts and full papers, assessed the literature, extracted data, drew 
conclusions for the PICOs, completed the evidence table, and wrote the 
manuscript.  JA checked the evidence table and reviewed the manuscript. EB 
assessed the literature, extracted data, checked and revised the evidence table, 
reviewed and critically revised the manuscript. Robert Fitridge screened the 
abstracts, assessed the literature, extracted data, checked and revised the 
evidence table, and reviewed the manuscript.  JPH checked the evidence table and 
reviewed the manuscript. KK checked the evidence table and reviewed the 
manuscript. JLM extracted data, checked the evidence table and reviewed the 
manuscript. SN checked the evidence table and reviewed the manuscript. JR 
checked the evidence table and reviewed the manuscript. MV checked the 
evidence table and reviewed the manuscript.  REZ extracted data, checked the 
evidence table and reviewed the manuscript. NCS assessed the literature, drew 
conclusions for the PICOs, checked and revised the evidence table, reviewed and 
critically revised the manuscript. RJH reviewed and provided final consensus for 
the data extraction, drew conclusions for the PICOs, reviewed and critically 
revised the manuscript. RachaelF acted as secretary of the working group, RJH as 






1. Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of 
diabetic foot ulceration: a systematic review and meta-analysis. Ann 
Med. Taylor & Francis; 2017;49(2):106–16.  
2. Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, et 
al. Prediction of outcome in individuals with diabetic foot ulcers: 
focus on the differences between individuals with and without 
peripheral arterial disease. The EURODIALE Study. Diabetologia. 2008 
Feb 23;51(5):747–55.  
3. Eraso LH, Fukaya E, Mohler ER, Xie D, Sha D, Berger JS. Peripheral 
arterial disease, prevalence and cumulative risk factor profile 
analysis. Eur J Prev Cardiol. SAGE PublicationsSage UK: London, 
England; 2014 Jun;21(6):704–11.  
4. Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of 
peripheral arterial disease and risk factors in persons aged 60 and 
older: data from the National Health and Nutrition Examination 
Survey 1999-2004. J Am Geriatr Soc. John Wiley & Sons, Ltd 
(10.1111); 2007 Apr;55(4):583–9.  
5. Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG. A 
prospective study of risk factors for diabetic foot ulcer - The Seattle 
diabetic foot study. Dia Care. 1999 Jul;22(7):1036–42.  
6. Elgzyri T, Larsson J, Thörne J, Eriksson K-F, Apelqvist J. Outcome of 
ischemic foot ulcer in diabetic patients who had no invasive vascular 
intervention. Eur J Vasc Endovasc Surg. 2013 Jul;46(1):110–7.  
7. Spreen MI, Gremmels H, Teraa M, Sprengers RW, Verhaar MC, van Eps 
RGS, et al. Diabetes Is Associated With Decreased Limb Survival in 
Patients With Critical Limb Ischemia: Pooled Data From Two 
Randomized Controlled Trials. Dia Care. American Diabetes 
Association; 2016 Nov;39(11):2058–64.  
8. Richter L, Freisinger E, Lueders F, Gebauer K, Meyborg M, Malyar NM. 
Impact of diabetes type on treatment and outcome of patients with 
peripheral artery disease. Diab Vasc Dis Res. 8 ed. 2018 
Nov;15(6):504–10.  
9. Golomb BA, Dang TT, Criqui MH. Peripheral Arterial Disease. 
Circulation; 2006 Aug 15;114(7):688–99.  
10. Apelqvist JAP, Lepäntalo MJA. The ulcerated leg: when to 
revascularize. Schaper N, Houtum W, Boulton A, editors. Diabetes 
Metab Res Rev.; 2012 Feb;28 Suppl 1(Suppl S):30–5.  
11. Jeffcoate WJ, Rasmussen LM, Hofbauer LC, Game FL. Medial arterial 
calcification in diabetes and its relationship to neuropathy. 
Diabetologia. Springer-Verlag; 2009 Dec;52(12):2478–88.  
12. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, 
Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of 
Patients With Lower Extremity Peripheral Artery Disease: A Report of 
the American College of Cardiology/American Heart Association Task 
Force on Clinical Practice Guidelines. Vol. 135, Circulation. 2017. pp. 
e726–79.  
13. Brownrigg JRW, Hinchliffe RJ, Apelqvist J, Boyko EJ, Fitridge R, Mills 
JL, et al. Effectiveness of bedside investigations to diagnose peripheral 
artery disease among people with diabetes mellitus: a systematic 
review. Diabetes Metab Res Rev. 2015 Sep 5;32 Suppl 1:n/a–n/a.  
14. Hinchliffe RJ, Forsythe RO, Apelqvist JAP, Boyko EJ, Fitridge RA, Hong 
JP, et al. IWGDF Guideline on diagnosis, prognosis and management of 
peripheral artery disease in patients with a foot ulcer and diabetes. 
Diabetes Metab Res Rev, in press.  
15. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred 
reporting items for systematic reviews and meta-analyses: the 
PRISMA statement. Vol. 62, Journal of Clinical Epidemiology. 2009. pp. 
1006–12.  
16. Garner P, Hopewell S, Chandler J, MacLehose H, Schunemann HJ, Akl 
EA, et al. When and how to update systematic reviews: consensus and 
checklist. BMJ : British Medical Journal. British Medical Journal 
Publishing Group; 2016;354.  
17. Bus SA, Van Netten JJ, Apelqvist JAP, Hinchliffe RJ, Lipsky BA, Schaper 
NC. Methodology of the IWGDF Guidelines 2019. Diabetes Metab Res 
Rev, in press.  
18. Boyko EJ. Ruling out or ruling in disease with the most sensitive or 
specific diagnostic test: short cut or wrong turn? Med Decis Making. 
Sage PublicationsSage CA: Thousand Oaks, CA; 1994 Apr;14(2):175–9.  
19. Jaeschke R, Guyatt GH, Sackett DL, Guyatt G, Bass E, Brill-Edwards P, 
et al. Users' Guides to the Medical Literature: III. How to Use an Article 
About a Diagnostic Test B. What Are the Results and Will They Help 
Me in Caring for My Patients? JAMA. American Medical Association; 
1994 Mar 2;271(9):703–7.  
20. Deeks JJ. Systematic reviews in health care - Systematic reviews of 
evaluations of diagnostic and screening. British Medical Journal. BMJ 
Publishing Group; 2001;323(7305):157–62.  
21. McGee S. Simplifying Likelihood Ratios. Journal of General Internal 
Medicine. Blackwell Science Inc; 2002 Aug 1;17(8):647–50.  
22. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The 
development of QUADAS: a tool for the quality assessment of studies 
of diagnostic accuracy included in systematic reviews. BMC Medical 
Research Methodology 2003 3:1. BioMed Central; 2003 Dec 1;3(1):25.  
23. Harbour R, Miller J, Guidelin SI. A new system for grading 
recommendations in evidence based guidelines. British Medical 
Journal. British Medical Journal Publishing Group; 
2001;323(7308):334–6.  
24. Liu F, Shen J, Zhao J, Zeng H, Li L, Zhao J, et al. Cystatin C: A Strong 
Marker for Lower Limb Ischemia in Chinese Type 2 Diabetic Patients? 
Xu A, editor. PLoS ONE. Public Library of Science; 2013;8(7).  
25. Clairotte C, Retout S, Potier L, Roussel R, Escoubet B. Automated 
Ankle-Brachial Pressure Index Measurement by Clinical Staff for 
Peripheral Arterial Disease Diagnosis in Nondiabetic and Diabetic 
Patients. Dia Care. American Diabetes Association; 2009 
Jul;32(7):1231–6.  
26. Williams DT, Harding KG, Price P. An evaluation of the efficacy of 
methods used in screening for lower-limb arterial disease in diabetes. 
Dia Care. American Diabetes Association; 2005 Sep;28(9):2206–10.  
27. Ezio F, Giacomo C, Maurizio C, Antonella Q, Vincenzo C, Francesco S. 
Evaluation of Feasibility of Ankle Pressure and Foot Oxymetry Values 
for the Detection of Critical Limb Ischemia in Diabetic Patients. 
Vascular and Endovascular Surgery. SAGE Publications; 2010 
Apr;44(3):184–9.  
28. Vriens B, D'Abate F, Ozdemir BA, Fenner C, Maynard W, Budge J, et al. 
Clinical examination and non-invasive screening tests in the diagnosis 
of peripheral artery disease in people with diabetes-related foot 
ulceration. Diabet Med. 2018 Jul;35(7):895–902.  
29. Premalatha G, Ravikumar R, Sanjay R, Deepa R, Mohan V. Comparison 
of colour duplex ultrasound and ankle-brachial pressure index 
measurements in peripheral vascular disease in type 2 diabetic 
patients with foot infections. J Assoc Physicians India. 2002 
Oct;50:1240–4.  
30. Lewis JEA, Owens DR. The Pulse Volume Recorder as a Measure of 
Peripheral Vascular Status in People with Diabetes Mellitus. Diabetes 
Technol Ther. 2010 Jan;12(1):75–80.  
31. VOGELBERG KH, STORK W. Measurement of Pulse Reappearance 
Time in Diagnosis of Peripheral Vascular-Disease in Diabetes. Dia 
Care. 1988 Apr;11(4):345–50.  
32. Tehan PE, Sebastian M, Barwick AL, Chuter VH. How sensitive and 
specific is continuous-wave Doppler for detecting peripheral arterial 
disease in people with and without diabetes? A cross-sectional study. 
Diab Vasc Dis Res. 3rd ed. 2018 Sep;15(5):396–401.  
33. Kumar MS, Lohiya A, Ramesh V, Behera P, Palepu S, Rizwan SA. 
Sensitivity and Specificity of Pulse Oximetry and Ankle-Brachial Index 
for Screening Asymptomatic Peripheral Vascular Diseases in Type 2 
Diabetes Mellitus. J Assoc Physicians India. 2016 Aug;64(8):38–43.  
34. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. 
Global vascular guidelines on the management of chronic limb-
threatening ischemia. Journal of Vascular Surgery. 2019 
Jun;69(6S):3S–125S.e40.  
35. Monteiro-Soares M, Russell DA, Boyko EJ, Jeffcoate WJ, Mills JL, 
Morbach S, et al. IWGDF Guidelines on the classification of diabetic 
foot ulcers. Diabetes Metab Res Rev, in press.  
36. Tehan PE, Barwick AL, Sebastian M, Chuter VH. Diagnostic accuracy of 
resting systolic toe pressure for diagnosis of peripheral arterial 
disease in people with and without diabetes: a cross-sectional 
retrospective case-control study. J Foot Ankle Res. BioMed Central; 
2017;10(1).  
37. Tehan PE, Bray A, Chuter VH. Non-invasive vascular assessment in the 
foot with diabetes: sensitivity and specificity of the ankle brachial 
index, toe brachial index and continuous wave Doppler for detecting 
peripheral arterial disease. J Diabetes Complicat. 2016;30(1):155–60.  
38. Dhanowar RK, Nath L, Tiwari PK. A Clinical Study of Peripheral 
Vascular Disease in Diabetes Mellitus With Special Reference to Ankle 
Brachial Pressure Index and Colour Doppler …. ijcmrcom 
39. Parameswaran GI, Brand K, Dolan J. Pulse oximetry as a potential 
screening tool for lower extremity arterial disease in asymptomatic 
patients with diabetes mellitus. Arch Intern Med. American Medical 
Association; 2005 Feb 28;165(4):442–6.  
40. Boyko EJ, Ahroni JH, Davignon D, Stensel V, Prigeon RL, Smith DG. 
Diagnostic utility of the history and physical examination for 
peripheral vascular disease among patients with diabetes mellitus. 
Journal of Clinical Epidemiology. 1997 Jun;50(6):659–68.  
41. Barshes NR, Flores E, Belkin M, Kougias P, Armstrong DG, Mills JLS. 
The accuracy and cost-effectiveness of strategies used to identify 
peripheral artery disease among patients with diabetic foot ulcers. 
YMVA. 2016 Dec;64(6):1682–.  
42. Dolan NC, Liu K, Criqui MH, Greenland P, Guralnik JM, Chan C, et al. 
Peripheral artery disease, diabetes, and reduced lower extremity 
functioning. Dia Care. 2002 Jan;25(1):113–20.  
43. Forsythe RO, Apelqvist J, Boyko EJ, Fitridge R, Hong JP, Katsanos K, et 
al. Performance of prognostic markers in the prediction of wound 
healing or amputation among patients with foot ulcers in diabetes: a 
systematic review. Diabetes Metab Res Rev, in press.  
44. Aboyans V, Ho E, Denenberg JO, Ho LA, Natarajan L, Criqui MH. The 
association between elevated ankle systolic pressures and peripheral 
occlusive arterial disease in diabetic and nondiabetic subjects. Journal 
of Vascular Surgery. 2008 Nov;48(5):1197–203.  
45. Hong Z, Xiao-ying L, Ya-jun S, Xi-lie L, Xue-sheng L, Zhao-yang L. 
Manifestation of lower extremity atherosclerosis in diabetic patients 
with high ankle-brachial index. Chin Med J. 2010;123(7):890–4.  
46. Hayden SR, Brown MD. Likelihood ratio: A powerful tool for 
incorporating the results of a diagnostic test into clinical 
decisionmaking. Ann Emerg Med. 1999 May;33(5):575–80.  
47. Hong Z, Li X-Y, Yajun Si, Xilie Lu, Liping Chen, Zhaoyang Liu. 
Manifestation of lower extremity atherosclerosis in patients with high 
ankle-brachial index. Diabetes & Vascular Disease. 2009 Aug 
28;9(4):160–4.  
48. Tehan PE, Bray A, Chuter VH. Non-invasive vascular assessment in the 
foot with diabetes: sensitivity and specificity of the ankle brachial 
index, toe brachial index and continuous wave Doppler for detecting 





Table 1: Interpretation of likelihood ratios and their effect on probability of disease (46) 
High likelihood ratios Low likelihood ratios Interpretation – affect on ability to 
rule in / rule out disease 
>10 <0.1 Large 
5-10 0.1-0.2 Moderate 
2-5 0.2-0.5 Small 





Table 2: Evidence table of all papers included in systematic review 
Source, year, ref Study 
design  & 
setting 
Population (age, sex, 
comorbidity, proportion with 
DM, number ulcerated etc) 
Index test; 





Index test performance 














83 DM; mean duration DM 12 
± 11; years, HbA1c 8.4 ± 
2.1%; presence foot ulcers 
NS; 60% with ‘normal clinical 
foot examination’ & presence 
2 pedal pulses; 48% 
neuropathy 
 
Mean age 63 ± 11 years; 71% 














Dop ABI (<0.9): Sensitivity 54%; 
Specificity 97%; PLR 17.0; NLR 
0.28 
 
Osc ABI (<0.9): Sensitivity 29.4%; 
Specificity 95.9%; PLR 7.9; NLR 
0.50  
 
Analysis by patient 
+ Incompressible ABI 
(>1.3 included in 
study but not 
considered an 
indicator of PAD) 
 
ABI measurement 
not blinded but was 
obtained by 
automated device 








92 DM; mean HbA1c 8.09- 
8.78%; mean duration DM 
ranged from 8.9-16.7 years 
between groups; presence 
foot ulceration NS; presence 
neuropathy NS 
 
Mean age 63±14 years; 78% 
male 
CAD 26%, CVD not reported 







Sensitivity 95%; Specificity 86%; 
PLR 6.8; NLR 0.06 
 
Analysis by patient 
+ Those with 
unobtainable ABIs 
categorized as high 
 
Exclusively Chinese 










100 T2DM; mean duration DM 
11.7 ± 8.1 years; HbA1c 9.5 ± 
2.0%; admitted to hospital; 
presence severe foot infection 
100%; presence neuropathy 
NS 
 
Mean age 59.5 ± 10.1 years; 
CAD/ CVD not reported 




Sensitivity 71%; specificity 89%; 
PLR 6.5, NLR 0.33  
 
Analysis by patient 

















57 T2DM; mean duration DM 
9 years; presence foot 
ulceration NS; presence 
neuropathy NS 
 
Mean age 63 years; male 
47%; CAD 18%; carotid 










ABI (<0.9): Sensitivity 63%; 
Specificity 97%; PLR 24.8; NLR 
0.38 
 
Pulse oximetry (2% lower than 
finger value/ elevation of leg): 
+ Combination of ABI 
& pulse oximetry 
(either test 
abnormal) -  
sensitivity 86%; 
specificity 92%; PLR 
11.29; NLR 0.15 
disease 2%; HTN 66%; 









any lower limb 
artery) 
Sensitivity 77%; Specificity 97%; 
PLR 30.0; NLR 0.23 
 






Patients with known 
LEAD/ symptoms of 
LEAD excluded  
 
Assessor of index 
test blinded to 
results reference test 
 





205 DM; T1DM 23; T2DM 182; 
duration DM NS; presence 
foot ulceration 0%; presence 
neuropathy NS 
 
Mean age 62.8 ± 12.9 years; 
male 105/205; CAD/ CVD not 
reported 









Sensitivity 91%; Specificity 67%; 
PLR 4.0; NLR 0.12 
 
Analysis by limb 
+ Patients with foot 


















79 limbs with DM; patients 
with DM NS; 85% T2DM; 74% 
male; mean age 63-69 years;  
mean duration DM ranged 
from 11-24 years between 
groups; presence foot 
ulceration 0%; 72% 
neuropathy 
 
CAD/ CVD not reported 
 

















Diabetes, no neuropathy:  
ABI (<0.9): Sensitivity 100%; 
Specificity 88%; PLR 8.0; NLR 
N/A 
TBI (<0.75): Sensitivity 91%; 
Specificity 65%; PLR 3.0; NLR 
0.1.Wave (loss of triphasic signal):  
Sensitivity 100%; Specificity 92%; 
PLR 13.0; NLR N/A 
 
Diabetic neuropathy: 
ABI: Sensitivity 53%; Specificity 
95%; PLR 11.0; NLR 0.49 
TBI: Sensitivity 100%; Specificity 
61%; PLR 3.0; NLR N/A 
Wave:  Sensitivity 94%; Specificity 
66%; PLR 3.0; NLR 0.09 
 
Analysis by limb 
+ Exclusions: active 





(>1.3 included in 
study but not 
considered an 
indicator of PAD) 
 
Unblinded study 





158 DM; mean duration DM 
16.1 years; 67% insulin 
therapy; 82.9% oral 
ABI ≤0.9 Peak tibial 
flow velocity 
(≤10 cm/s) 
Sensitivity 99%; Specificity 58%; 
PLR 2.4; NLR 0.02 
 
+ 7.6% of DM patients 






medication; presence foot 
ulceration NS; presence 
neuropathy NS 
 
Mean age 68 years (range30-
100); 88% males 
CVD/ CAD not reported 
 
 
Analysis by patient Unblinded study 





261 CLI and DM; mean 
duration DM 18 ± 12 years; 
60.9% insulin therapy; 39.1% 
oral therapy; presence of foot 
ulceration 94%; 82% 
neuropathy 
 
Mean age 76 ± 8 years 
(females), 71.6 ± 8.7 years 
(males); males 66.5%, HTN 
46.0%; CAD 20.3%; CVD 
24.5% 
 
CLI definition: ankle pressure 
<70mmHg and TcPo2 at 
dorsum of foot <50mmHg 
Ankle pressure <70 
mm Hg and TcPO2 














Ankle pressure: Sensitivity 67%; 
Specificity N/A 
 
TcPO2: Sensitivity 82%; Specificity 
N/A 
 
Analysis by patient 
+ Cohort of patients 
with DM and rest 
pain/ foot lesions. 
 
Unrecordable ankle 
pressures due to 
arterial calcification 
or absent foot pulses 
were not excluded 
 
100% of patients 
had a stenosis >50% 
of lumen on DSA 
therefore no 
















20 DM; 30% NIDDM; mean 
duration DM 15 ± 10 years 
 
Mean age 61 ± 9; 65% male;  
with angiographically 
confirmed  PAD were 
selected; gangrene 47%, 
CAD/ CVD not reported; 
gangrene of the foot in 47%; 
presence neuropathy NS 
 
Pulse reappearance 
time (measured with 








PRT: Sensitivity 41%; Specificity 
92%; PLR 5.1; NLR 0.64 
 
ABI: Sensitivity 36%; Specificity 
93%; PLR 5.1; NLR 0.69 
 
Analysis by arterial segments 
+ No definition 
provided for cut-offs 
for pathological PRT 
or ABI 
 









80 with Type 2 DM; no further 
info given. No follow up data 
reported. 
ABI <0.9 CDU: 
presence of 
atheroscleroti
c plaques or 
arterial 
calcification 
ABI <0.9 sensitivity 71.4%; 
specificity 97%; PPV 83.3%; NPV 
94.1%; PLR 23.80; NLR 0.29. 
 
Analysis by patient 
 Minimal clinical 
information  
 













Sub-group analysis of 176 
patients with DM. Age 74.65 
years; male 65%, ever 
smoked 58%; active ulceration 
3%; claudication 9%. 
 
CAD/CVD/neuropathy not 




















CWD sensitivity 82.76%; 





Analysis by patient 
 Sub-group analysis 
of DM patients is 
clearly reported 
therefore this study 
is included despite 
overall <80% DM. 
Sensitivity best in 
patients with 
occlusive disease 
(85.26%) and worst 
in patients with 
>75% stenosis 
(54.55%). In patients 
with MAC (n=45), 
sensitivity 87.5%; 
specificity 69.23%; 
PLR 2.84; NLR 0.18. 









Sub-group analysis of 176 with 
DM. Age 74.60 years; male 
65%; history of foot 






No follow up data reported. 


























Toe pressure sensitivity 73.73%; 




Analysis by patient 
 Also analysed 




severity.  Best 
sensitivity in patients 
(n=39; 22.16%) with 
proximal and distal 
disease (79.49%) 
and those (n=11; 


















Sub-group analysis of 72 with 
DM. Age 73 years; male 65%; 
neuropathy 12%; ever smoked 
58%; cardiovascular disease 
31%. 
 
Neuropathy or ulceration not 
reported. 
Follow up not reported. 
 
ABI ≤0.9 or ≥1.4 
 
CWD: presence of 
PAD= loss of multi-
phasic patterns in DP 
or PT demonstrated 
by low-resistance, 
slow systolic 
acceleration and no 









ABI: sensitivity 45.16%; specificity 
92.68%; PLR 6.17; NLR 0.59; 
PPV 82.35; NPV 69.09. 
 
CWD: sensitivity 74.19%; 
specificity 92.86%; PLR 10.29; 
NLR 0.28; PPV 88.46; NPV 82.98. 
 
TBI: sensitivity 63.63%; specificity 
82.05%; PLR 3.55; NLR 0.44; 
PPV 75.00; NPV 72.73. 
 
Analysis by patient 
 Assessor blinded to 
reference test 







120 patients with Type 2 DM; 
asymptomatic PAD; 0% 
ulceration. No further clinical 
information given.  
 




(SpO2): presence of 
PAD= toe saturation 
less than finger 
saturation by <2% or 
if foot saturation 
decreased by >2% 






any one artery 
ABI: sensitivity 70.3%; specificity 
87.2%; PPV 61.3%; NPV 91.0%; 
PLR 5.49; NLR 0.34. 
 
Pulse oximetry: sensitivity 74.1%; 
specificity 95.7%; PPV 83.3%; 
NPV 92.7%; PLR 17.23; NLR 0.27 
 
Parallel testing (ABI + SpO2 
combined): sensitivity 92.3%; 
specificity 83.3%; PLR 5.53; NLR 
0.09 
 
Analysis by patient 
   Assessor of index 
test blinded to 
results reference test 
 








60 patients with DM and new 
onset foot ulceration; 25% 
inpatients.  Age 66 years; 
male 75%; duration of 
diabetes 2 years; current 
smokers 7%, hypertension 
73%; CVD 7%; CAD 16%; 
CKD 23%; neuropathy 85%; 
active infection 32%  
Clinical examination: 
hair loss, muscle 
atrophy, dependent 
rubor, cool skin, 
blue/purple skin, 
capillary refill time, 











Clinical examination: Pedal pulse 
assessment: sensitivity 0.55, 
specificity 0.60; PPV 0.41, NPV 
0.73; PLR 1.38, NLR 0.75.  Hair 
loss: sensitivity 0.8, specificity 
0.44; PPV 0.42, NPV 0.81; PLR 
1.42, NLR 0.46. Atrophy: 
sensitivity 0.5, specificity 0.87; 
PPV 0.67, NPV 0.77; PLR 3.9, 
 Assessor blinded to 
results reference test 
* QUADAS quality assessment: High quality (++): majority of criteria met; Acceptable (+): most criteria met; Low quality (0): Either most criteria not met , or significant flaws relating to key aspects of study 

























NLR 0.57. Dependent rubor: not 
discriminatory.  Cool skin: 
sensitivity 0.3, specificity 0.9; PPV 
0.6, NPV 0.71; PLR 2.93, NLR 
0.78. Blue/purple skin: not 
discriminatory. Capillary refill: 
sensitivity 0.42, specificity 0.63; 
PPV 0.36, NPV 0.69; PLR1.14, 
NLR 0.92. Venous filling: not 
discriminatory.  
 
Ankle pressure: sensitivity 0.47, 
specificity 0.79; PPV 0.53, NPV 
0.75; PLR 2.25, NLR 0.67.  Toe 
pressure: sensitivity 0.45, 
specificity 0.97; PPV 0.90, NPV 
0.78; PLR 17.55, NLR 0.56.  TBI: 
sensitivity 0.89, specificity 0.45; 
PPV 0.45, NPV 0.89; PLR 1.63, 
NLR 0.24. ABI: sensitivity 0.68, 
specificity 0.59; PPV 0.46, NPV 
0.79; PLR 1.69, NLR 0.53.  
 
Pole test: sensitivity 0.28, 
specificity 0.97; PPV 0.83, NPV 
0.73; PLR 10.29, NLR 0.74. 
 
TcPO2: sensitivity 0.28, specificity 
0.66; PPV 0.28, NPV 0.66; PLR 
0.81, NLR 1.10. 
 
Tibial waveforms: sensitivity 0.85, 
specificity 1; PPV 1, NPV 0.93; 
PLR diagnostic; NLR 0.15 (the 
definition of PAD included 
monophasic waveforms therefore 
specificity / PPV are 1 and PLR is 
infinite and diagnostic. 
 
Analysis by patient. 
Abbreviations: ABI indicates ankle brachial index; CAD, coronary artery disease; CDU, colour duplex ultrasonography; CHD, coronary heart disease; CLI, critical limb ischaemia; CVA, cerebrovascular 
accident; CWaD, colour wave Doppler; CWD, continuous-wave Doppler;  DM, diabetes mellitus; Dop-ABI, Doppler ABI; DP, dorsalis pedis artery; DSA, digital subtraction angiography; DUS, duplex 
ultrasound; HbA1c, glycosylated haemoglobin; HTN, hypertension; LEAD, lower extremity arterial disease; LLI, lower limb ischaemia; MAC, medial arterial calcification; NA, not applicable (cannot be 
calculated). NLR, negative likelihood ratio; NPV, negative predictive value; NS, not stated; Osc-ABI, oscillatory ABI; PAD, peripheral artery disease; PLR positive likelihood ratio; PPV, positive predictive 
value; PN+, with peripheral neuropathy; PN-, without peripheral neuropathy; PSV, peak systolic velocity; PT, posterior tibial artery; ROC, receiver operator characteristic; SpO2, peripheral arterial oxygen 
saturation; TBI, toe brachial index; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
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database searching  




























(n = 8751) 
Full-text articles assessed 
for eligibility 
(n = 81) 
Full-text articles excluded 
(n = 76) 
Total studies included in 2019 qualitative synthesis 
(n = 15) 
Previous search (June 2014) – total 
records screened (n= 6629) 
Previous search (June 2014) – final 
articles included in 2015 systematic 
review (n=10) 
Previous search (June 2014) – final 
articles excluded from 2019 
systematic review (n=1) 
PREVIOUS SEARCH (June 2014)  CURRENT SEARCH (June 2018)  
Abstracts screened 
(n = 295) 
Current search (June 2018) – final 
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review (n=6)  
Previous search (June 2014) – final 
articles included in 2019 systematic 
review (n=9) 
